Optimal Stent Deployment Strategy of Contemporary Stents (PERFECTPSP)

January 30, 2024 updated by: Dr. Rohit M. Oemrawsingh, Albert Schweitzer Hospital

OPtimal stEnt Deployment stRategy oF Contemporary sTents

The primary objective is to evaluate whether a standard pre- and postdilatation (PSP strategy) of the modern DES results in a more optimal stent implantation compared to DS as evaluated by OCT in patients with stable coronary artery disease. The secondary clinical objective is to evaluate clinical cardiovascular outcomes in patients with stable coronary artery disease treated with the PSP strategy.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Rationale: Historically, when coronary stents were initially introduced, the standard and mandatory treatment of a significant stenosis was with pre-dilation prior to stent placement. In the 2000s, several studies found no significant difference in clinical outcome between the two different stent implantation techniques: direct stenting (DS) versus the conventional stenting after pre-dilation (CS). Consequently, the stent implantation technique has become "unprotocolarised", i.e. each operator has their own, individual set of reasons for applying or avoiding pre- and post-dilation in specific conditions. However, these trials do not apply to the current/modern clinical practice of coronary stenting. The current patient population undergoing percutaneous coronary intervention (PCI) cannot be compared to the population that was treated in the early 2000s. The same applies for stent design. Stents have undergone several major transformations in the last 20 years. Furthermore, the events rates after PCI have significantly decreased within the last decades due to better stent design and improved background pharmacological therapy.

Imaging studies have revealed that an optimal stent result is not achieved in a high percentage of stent implantations. Post-hoc studies have demonstrated that the optimization of the implantation technique could reduce adverse cardiac events over time. As a result of these findings, the PSP concept: Pre-dilation, Sizing and Post-dilation was introduced. Whether routine pre- and postdilatation compared to DS also results in optimal stent implantation in contemporary drug-eluting stents (DES) has not been investigated and, hence is currently unknown.

Objective: The primary objective is to evaluate whether a standard pre- and postdilatation (PSP strategy) of the modern DES results in a more optimal stent implantation compared to DS as evaluated by OCT in patients with stable coronary artery disease. The secondary clinical objective is to evaluate clinical cardiovascular outcomes in patients with stable coronary artery disease treated with the PSP strategy.

Study Type

Interventional

Enrollment (Estimated)

248

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Dordrecht, Netherlands
        • Recruiting
        • Albert Schweitzer Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 100 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Stable angina patients or acute coronary syndrome patients with bystander stable coronary artery disease
  2. With one or more significant epicardial stenosis in native coronary arteries suitable for direct stenting, according to the judgement of treating operator.

    The use of fractional flow reserve (FFR) or resting indices like iFR and RFR to assess lesion severity is encouraged.

  3. Subject must be at least 18 years of age
  4. Written consent to participate in the study

Exclusion Criteria:

  1. Lesions not suitable for direct stenting, like (sub)-total stenosis, severely calcified lesions
  2. Culprit lesions of acute coronary syndrome cannot be randomized to the trial. After successful treatment of the ACS culprit lesion, patients however can be randomized in the trial in case of remaining stable non-culprit lesions that thought to be stented directly of during a staged procedure.
  3. Lesions not suitable for OCT catheter delivery and imaging, e.g. left main or ostial right coronary artery stenosis, lesions in coronary bypass grafts or tortuous anatomy
  4. Treatment for in-stent restenosis
  5. Bifurcation lesions in which a two-stent technique or a proximal postdilatation is planned.
  6. Treatment of coronary artery bypass grafts
  7. Creatine Clearance ≤ 30 ml/min/1.73 m2 (as calculated by MDRD formula for estimated GFR)
  8. Known hypersensitivity or allergy for cobalt chromium
  9. Known comorbidity associated with a life expectancy < 1 year
  10. Unable to understand and follow study-related instructions or unable to comply with study protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PSP technique

The definitions of the PSP technique are:

  • Predilatation is mandatory with a balloon diameter equal to or maximally 0.5 mm less than the distal reference vessel diameter. We hypothesize that this lesion preparation and fracture of the calcium may result in better stent apposition, less recoil and higher minimal stent area (MSA) Also see endpoints.
  • The DES should be deployed at 2 atm. above the nominal pressure. This relatively low stent deployment pressure may prevent stent edge dissections.
  • The postdilatation is mandatory with a shorter length and (at least 0.25mm) larger diameter non-compliant balloon at 16 atm. The apposition, minimal stent area (MSA) and recoil may improve with this large, high pressure postdilatation. The slightly shorter balloon can prevent edge dissections.
percutaneous coronary intervention
Active Comparator: Direct Stenting
• The DES is directly placed without any lesion preparation and deployed at a pressure at the discretion of the operator. Ideally a pressure would be achieved in which angiographic expansion of the DES is complete (without significant dog-boning)
percutaneous coronary intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Suboptimal stent results which is defined as a composite of major stent underexpansion and major edge dissection measured by OCT at lesion level directly after completion of the stent implantation according to the protocol
Time Frame: During procedure

Stent malapposition (categorical variable) is defined as:

  • Unacceptable stent expansion: The minimal stent area (MSA) of the proximal segment is <90% of the proximal lumen area, and/or the MSA of the distal segment is <90% of the distal reference lumen area on OCT OR
  • Presence of incompletely apposed stent struts on OCT more than 3mm long (defined as stent struts clearly separated from the vessel wall (lumen border/plaque border) without any tissue behind the struts with a distance from the adjacent intima of ≥0.2 mm and not associated with any side branch: i.e. the Prati criterium)

Edge dissections (categorical variable) will be presented as:

• Dissections on OCT of ≥60 degrees of the circumference of the vessel at the site of dissection and ≥3 mm in length

During procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
MACE
Time Frame: 1-,3- and 5-year follow-up
a composite of time- to-first event rate of cardiac death, target vessel MI, ischemia-driven target vessel revascularization (TVR)
1-,3- and 5-year follow-up
Target Lesion Failure (TLF)
Time Frame: 1-,3- and 5-year follow-up
defined as cardiac death, target vessel- myocardial infarction and clinically indicated target lesion revascularization)
1-,3- and 5-year follow-up
Target Vessel Failure (TVF)
Time Frame: 1-,3- and 5-year follow-up
defined as cardiac death, target vessel- myocardial infarction and clinically indicated target vessel revascularization
1-,3- and 5-year follow-up
All cause mortality
Time Frame: 1-,3- and 5-year follow-up
1-,3- and 5-year follow-up
Cost-effectiveness analysis
Time Frame: 1-,3- and 5-year follow-up
total number of stent, balloons, wires and repeat hospitalizations due to MACE
1-,3- and 5-year follow-up
Minimal stent area (MSA) (mm^2)
Time Frame: During procedure
During procedure
Acute recoil (percent)
Time Frame: During procedure
assessed on coronary angiography
During procedure
Stent malapposition (percent)
Time Frame: During procedure
defined as frequency of incompletely apposed stent struts (defined as stent struts clearly separated from the vessel wall (lumen border/plaque surface) without any tissue behind the struts with a distance from the adjacent intima of ≥0.2 mm and not associated with any side branch).
During procedure
Mean stent expansion (percent):
Time Frame: During procedure
mean stent area (stent volume/analysed stent length) divided by the average of proximal and distal reference lumen areas x 100
During procedure
Intra-stent plaque protrusion and thrombus
Time Frame: During procedure
defined as any intraluminal mass protruding at least 0.2 mm within the luminal edge of a stent strut
During procedure
Post OCT stent result optimalization (percent)
Time Frame: During procedure
composite of additional post-dilation and/or stent placements after OCT
During procedure
Stent Thrombosis
Time Frame: 1-,3- and 5-year follow-up
definite or probable; Academic Research Consortium (ARC) definition
1-,3- and 5-year follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Rohit Oemrawsingh, MD, PhD, Albert Schweitzer Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2022

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

September 1, 2029

Study Registration Dates

First Submitted

December 2, 2021

First Submitted That Met QC Criteria

March 14, 2022

First Posted (Actual)

March 23, 2022

Study Record Updates

Last Update Posted (Estimated)

February 1, 2024

Last Update Submitted That Met QC Criteria

January 30, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • PERFECT 001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.